Opinion|Videos|January 13, 2025

Decision Points for Using CAR T-Cell Therapy in Early Lines of Treatment

Author(s)Ajai Chari, MD, Anupama Kumar, MD, Darren Pan, MD

Panelists discuss how, when considering earlier lines of CAR T-cell therapy for relapsed/refractory multiple myeloma, key institutional factors include patient fitness/age, cytogenetic risk status, prior therapy response duration, and BCMA expression levels. Manufacturing timelines, financial considerations, and center-specific outcomes data also influence timing decisions. For patients receiving early-line CAR T therapy, subsequent treatment options typically focus on novel agent combinations or clinical trials exploring additional cellular therapies, with choices guided by response duration to CAR T and the patient’s individual disease characteristics and treatment goals.

Episodes in this series

EP. 1 Introduction and CAR-T Therapy in Earlier Lines of Treatment for R/R Multiple Myeloma

EP. 1 Introduction and CAR-T Therapy in Earlier Lines of Treatment for R/R Multiple Myeloma

EP. 2 Decision Points for Using CAR T-Cell Therapy in Early Lines of Treatment

EP. 2 Decision Points for Using CAR T-Cell Therapy in Early Lines of Treatment

EP. 3 Second-Line Treatment for R/R Multiple Myeloma: Who Is the “Right Patient”?

EP. 3 Second-Line Treatment for R/R Multiple Myeloma: Who Is the “Right Patient”?

EP. 4 Referral Process for CAR T-Cell Therapy: Initial Contact Through Patient Evaluation and Selection

EP. 4 Referral Process for CAR T-Cell Therapy: Initial Contact Through Patient Evaluation and Selection

EP. 5 CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy

EP. 5 CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy

EP. 6 Co-Management and Co-Monitoring of Patients Receiving CAR T-Cell Treatment: Transitions Between the Academic and Community Centers

EP. 6 Co-Management and Co-Monitoring of Patients Receiving CAR T-Cell Treatment: Transitions Between the Academic and Community Centers

EP. 7 Management of Adverse Events of Special Interest in Patients Receiving CAR -T-Cell Therapy for R/R Multiple Myeloma: Diarrhea, Guillain-Barrée Syndrome, Parkinson’s Disease, and Secondary Malignancies

EP. 7 Management of Adverse Events of Special Interest in Patients Receiving CAR -T-Cell Therapy for R/R Multiple Myeloma: Diarrhea, Guillain-Barrée Syndrome, Parkinson’s Disease, and Secondary Malignancies

EP. 8 Example of Successful Collaboration with a Referring Community Practice

EP. 8 Example of Successful Collaboration with a Referring Community Practice

EP. 9 CAR T-Cell Therapy in Multiple Myeloma: Lessons Learned and Key Takeaways

EP. 9 CAR T-Cell Therapy in Multiple Myeloma: Lessons Learned and Key Takeaways

Video content above is prompted by the following:

What are the key factors that influence your institution’s decision to utilize CAR T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma?
If you choose to utilize CAR T in earlier lines of therapy, what might you do next and why?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies

November 15th, 2026

Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Managing Emergencies During Outpatient Bispecific Step-Up Dosing

November 14th, 2026

Managing Emergencies During Outpatient Bispecific Step-Up Dosing

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Why Caregivers Are Critical During Bispecific Step-Up Dosing

November 13th, 2026

Why Caregivers Are Critical During Bispecific Step-Up Dosing

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

REMS Certification and Team-Wide Training for Bispecific Administration in Multiple Myeloma

November 13th, 2026

REMS Certification and Team-Wide Training for Bispecific Administration in Multiple Myeloma

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.

Optimal Cytoreduction and Early Trial Referral in High-Risk Newly Diagnosed Myeloma

November 13th, 2026

Optimal Cytoreduction and Early Trial Referral in High-Risk Newly Diagnosed Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.

What Sustained MRD Negativity Can Settle About Stopping Myeloma Maintenance

November 12th, 2026

What Sustained MRD Negativity Can Settle About Stopping Myeloma Maintenance

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.

In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.

November 11th, 2026

Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma Cohort

In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.

European Commission Expands Melflufen Label to Third-Line Multiple Myeloma

November 10th, 2026

European Commission Expands Melflufen Label to Third-Line Multiple Myeloma

Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.

Trending on CancerNetwork

FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC

Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011

Managing Emergencies During Outpatient Bispecific Step-Up Dosing

ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals

Survival in Childhood and Adolescent Cancers Improves, but Racial Disparities Persist